Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Single Dose IPX203 in Advanced Parkinson's Disease
NCT02271503Phase 2Completed
- Sponsor
- Impax Laboratories
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by Impax Laboratories. Started Nov 2015; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02271503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271503.